Citizen Health, a startup founded by a mother of a rare disease patient, has launched an AI-powered advocate that automates insurance appeals, schedules appointments, and connects families to others facing the same conditions. The platform currently serves over 8,000 rare disease patients across more than 350 diseases, with 16 pharmaceutical companies using its aggregated patient data to accelerate drug development .

Why Are Rare Disease Families Drowning in Administrative Work?

When Nasha Fitter's youngest daughter was diagnosed with FOXG1 syndrome, a rare genetic neurodevelopmental disorder, in 2017, she encountered a problem that defines the rare disease experience: almost no information exists about the condition, and families are left to piece together care on their own. "There was really nothing being done," Fitter explained. "Just getting day-to-day answers to my questions and the issues I was facing was really unsystematic and random. It was basically going to Facebook and hoping someone would answer my question" .

The burden is staggering. Parents managing rare diseases spend an average of 53 hours per week on care-related tasks beyond ordinary parenting, according to Citizen Health CEO Farid Vij. For context, that is more than a full-time job dedicated solely to navigating medical systems, insurance, and finding specialists who have even seen a handful of patients with the same condition .

Fitter, a technology entrepreneur, recognized that artificial intelligence could solve this problem at scale. Working with fellow tech entrepreneur Vij, she co-founded Citizen Health in 2023 to build what they call an "AI advocate" for the rare disease community. The platform combines patient data, medical records, and community experiences to create a resource that families can actually use .

How Does Citizen Health's AI Advocate Actually Work?

• Appointment Scheduling: The AI handles the logistical burden of booking appointments with specialists, reducing the administrative overhead that consumes hours of family time each week.
• Insurance Navigation: The system automates insurance appeals and helps families understand coverage options, a task that typically requires expertise most families don't possess.
• Patient Matching: The AI connects patients and families with others managing the same rare condition, creating a network of shared knowledge and experience that didn't exist before.
• Clinical Trial Alerts: The platform identifies relevant clinical trials and notifies patients when new research opportunities become available for their specific condition.
• Medical Record Monitoring: The system alerts families when something in their medical records warrants attention, catching issues that might otherwise be missed.

The platform is free for patients to use. When they join, they can opt into sharing their anonymized medical records, genetic information, and health experiences with researchers. Currently, 98.3% of patients choose to share their data, recognizing that collective information accelerates research .

Vij explained the core mission: "The single biggest thing that you can have that will benefit you if you are a patient with a rare disease is an advocate in your corner." For most families, that advocate role falls on a parent or loved one, consuming enormous amounts of time and emotional energy. The AI handles the routine work, freeing families to focus on actual care and quality of life .

Vij

How Is This Accelerating Drug Development?

The real innovation extends beyond patient support. Citizen Health has built one of the largest rare patient data networks in existence, with over 8,000 patients across more than 350 diseases sharing their information. Sixteen pharmaceutical companies are already using this aggregated data to advance treatments .

The results are striking. Vij stated: "We've been able to reduce timelines to get these therapies to market where they're actually built on what patients need by 30%-50%." That acceleration matters enormously in rare disease, where every month of delay means patients and families continue suffering without treatment options .

Vij

Fitter's own foundation, the FOXG1 Research Foundation, provides a concrete example. Using data from Citizen Health, the foundation analyzed medical records from other FOXG1 patients and discovered that the most important endpoint for treatment should be movement disorders, not seizures as previously assumed. This insight, drawn from the collective experience of the patient community, allowed the foundation to design a more effective clinical trial .

The FDA even recognized the value of this approach. Fitter's foundation recently had a Type D meeting with the FDA and was permitted to use patient natural history data from Citizen Health as the placebo control arm in their trial. This decision allowed them to skip a full Phase 3 trial and placebo arm, saving approximately $80 million in development costs while accelerating the path to treatment .

"In rare disease, a parent will spend on average 53 hours a week taking care above and beyond the ordinary parenting that anyone might have to do. So it's giving a lot of those hours back, but also driving much better outcomes for patients because you're learning from the collective wisdom of the community," said Farid Vij.

Farid Vij, CEO at Citizen Health

Why Does This Matter Beyond Rare Disease?

The broader implication is that AI works differently when trained on the right data. General-purpose AI models struggle with rare diseases because, by definition, there is little public information to learn from. "There's been no research done, there are no approved therapies, and even the top expert has seen only a few patients, so there is nothing for the model to draw from," Vij explained .

Citizen Health solved this by building a specialized dataset from the ground up, working directly with patients and advocacy groups. This approach demonstrates that AI's value in healthcare isn't just about processing scale; it's about having the right information from the right communities. The platform shows how technology can democratize expertise that was previously available only to families with resources to hire advocates or start foundations themselves .

The company has raised $44 million since its 2023 launch, including a $30 million Series A funding round in August 2025 led by 8VC, with backing from Headline, Transformation Capital, and the Chan Zuckerberg Initiative. This funding validates the market opportunity and the potential for AI-powered patient advocacy to reshape how rare diseases are managed and treated .

Fitter, who serves as chief business officer and uses the platform to manage her own daughter's care, summed up the impact: "It's a game changer for the individual patient, getting better care and making better decisions day-to-day. For our foundation, if we didn't have Citizen we would not be dosing our first patient this year" .